X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs NATCO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA NATCO PHARMA ALEMBIC PHARMA/
NATCO PHARMA
 
P/E (TTM) x 24.2 16.0 151.5% View Chart
P/BV x 6.8 17.2 39.3% View Chart
Dividend Yield % 0.7 0.7 104.7%  

Financials

 ALEMBIC PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
NATCO PHARMA
Mar-14
ALEMBIC PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs792877 90.3%   
Low Rs443424 104.6%   
Sales per share (Unadj.) Rs167.0223.4 74.8%  
Earnings per share (Unadj.) Rs38.231.1 122.8%  
Cash flow per share (Unadj.) Rs42.040.3 104.3%  
Dividends per share (Unadj.) Rs4.005.00 80.0%  
Dividend yield (eoy) %0.60.8 84.3%  
Book value per share (Unadj.) Rs84.9219.5 38.7%  
Shares outstanding (eoy) m188.5233.07 570.1%   
Bonus/Rights/Conversions -PA-  
Price / Sales ratio x3.72.9 127.0%   
Avg P/E ratio x16.220.9 77.3%  
P/CF ratio (eoy) x14.716.1 91.1%  
Price / Book Value ratio x7.33.0 245.5%  
Dividend payout %10.516.1 65.1%   
Avg Mkt Cap Rs m116,38321,504 541.2%   
No. of employees `000NANA-   
Total wages/salary Rs m4,2141,128 373.7%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m31,4877,389 426.1%  
Other income Rs m55167 33.0%   
Total revenues Rs m31,5427,556 417.4%   
Gross profit Rs m10,0601,793 561.0%  
Depreciation Rs m722304 237.2%   
Interest Rs m37366 10.0%   
Profit before tax Rs m9,3561,290 725.4%   
Minority Interest Rs m046 0.0%   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,160309 699.8%   
Profit after tax Rs m7,1941,027 700.2%  
Gross profit margin %31.924.3 131.6%  
Effective tax rate %23.123.9 96.5%   
Net profit margin %22.813.9 164.3%  
BALANCE SHEET DATA
Current assets Rs m15,0663,681 409.2%   
Current liabilities Rs m7,6743,123 245.8%   
Net working cap to sales %23.57.6 310.5%  
Current ratio x2.01.2 166.5%  
Inventory Days Days6789 74.8%  
Debtors Days Days4159 69.2%  
Net fixed assets Rs m8,2377,685 107.2%   
Share capital Rs m377331 114.0%   
"Free" reserves Rs m15,4166,670 231.1%   
Net worth Rs m16,0057,259 220.5%   
Long term debt Rs m0955 0.0%   
Total assets Rs m24,59411,957 205.7%  
Interest coverage x255.24.5 5,644.2%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.30.6 207.2%   
Return on assets %29.411.7 252.3%  
Return on equity %44.914.2 317.6%  
Return on capital %58.720.7 283.1%  
Exports to sales %55.739.4 141.6%   
Imports to sales %10.45.7 182.9%   
Exports (fob) Rs m17,5512,908 603.6%   
Imports (cif) Rs m3,283421 779.4%   
Fx inflow Rs m17,8113,445 516.9%   
Fx outflow Rs m5,318703 756.7%   
Net fx Rs m12,4932,743 455.5%   
CASH FLOW
From Operations Rs m9,3041,440 646.0%  
From Investments Rs m-3,105-1,089 285.1%  
From Financial Activity Rs m-1,959-353 555.5%  
Net Cashflow Rs m4,240-1 -284,563.8%  

Share Holding

Indian Promoters % 74.1 52.0 142.4%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 2.9 7.8 37.0%  
FIIs % 9.1 16.6 54.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 26.0 53.5%  
Shareholders   49,328 25,395 194.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Up Over 240 Points; Rupee Touches Record Low(12:30 pm)

After opening the day in the green, stock markets in India have continued their momentum and are presently trading on a positive note.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Should You Buy These Mouthwatering High Dividend Stocks?(Profit Hunter)

Aug 1, 2018

Many stocks are yielding dividends even upwards of 4%-5%. Here are the kinds you should pick, and the ones to avoid.

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

NFO - Axis Equity Hybrid Fund: A Worthy Proposition?(Outside View)

Aug 1, 2018

PersonalFN explains if NFO: Axis Equity Hybrid Fund, would be a worthy proposition currently.

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Aug 14, 2018 02:03 PM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS